Skip header and navigation

8 records – page 1 of 1.

Cinacalcet (Sensipar) for secondary hyperparathyroidism in chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1465
Available Online
View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinac…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Cinacalcet
Renal Insufficiency, Chronic - drug therapy
Hyperparathyroidism, Secondary - drug therapy
Subjects (LCSH)
Chronic renal failure
Hyperparathyroidism
Kidneys--Diseases--Treatment
Abstract
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinacalcet, possible side effects, and how to store this medication.
Notes
Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
Previous title: Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)
Responsibility
Prepared by: Renal Program
Pamphlet Number
1465
Less detail

Dispositif hormonal intra-utérin (avec lévonorgestrel)

https://libcat.nshealth.ca/en/permalink/chpams36598
Nova Scotia Health Authority. Nova Scotia Women's Choice Clinic. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
2019
Available Online
View Pamphlet
Un dispositif hormonal intra-utérin (DIU avec lévonorgestrel) est un petit dispositif composé d’une matière plastique souple et d’une hormone appelée lévonorgestrel, qui est inséré dans l’utérus par un fournisseur de soins de santé primaires (médecin de famille ou infirmière praticienne). Il sert à prévenir les grossesses. Le dépliant explique comment fonctionne le DIU avec lévonorgestrel, quels sont ses avantages et ses inconvénients et ce qui se passe quand il est inséré dans l’utérus, de mêm…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Women's Choice Clinic
Alternate Title
Hormonal (levonorgestrel) intrauterine devices (IUDs)
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
French
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Intrauterine Devices
Contraception - methods
Subjects (LCSH)
Intrauterine contraceptives
Contraception
Abstract
Un dispositif hormonal intra-utérin (DIU avec lévonorgestrel) est un petit dispositif composé d’une matière plastique souple et d’une hormone appelée lévonorgestrel, qui est inséré dans l’utérus par un fournisseur de soins de santé primaires (médecin de famille ou infirmière praticienne). Il sert à prévenir les grossesses. Le dépliant explique comment fonctionne le DIU avec lévonorgestrel, quels sont ses avantages et ses inconvénients et ce qui se passe quand il est inséré dans l’utérus, de même que le déplacement, la perte et le retrait du DIU avec lévonorgestrel. Le dépliant liste aussi les symptômes qui requièrent immédiatement des soins médicaux.
This is a French translation of the English pamphlet 2006, "Hormonal (levonorgestrel) Intrauterine Devices (IUDs)". A hormonal intrauterine device (IUD) is a small device made of flexible plastic with a hormone called levonorgestrel that is placed inside the uterus by a primary health care provider (family doctor or nurse practitioner). It is used to prevent pregnancy. This pamphlet explains how a hormonal IUD works, the pros and cons of a hormonal IUD, what will happen when the IUD is inserted, movement or loss of the IUD, and IUD removal. A list of symptoms that require immediate medical attention is also provided.
Responsibility
Prepared by: Nova Scotia Women's Choice Clinic
Pamphlet Number
2019
Less detail

Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke

https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
2217
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Neoplasms
Stroke
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Cancer
Cerebrovascular disease
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
Responsibility
Prepared by: Renal Program
Pamphlet Number
2217
Less detail

Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1493
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medications that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This pamphlet explains how to take and store this medication, and lists possible side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Subjects (LCSH)
Chronic renal failure--Complications
Renal anemia
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medications that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This pamphlet explains how to take and store this medication, and lists possible side effects.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1493
Less detail

Hormonal (levonorgestrel) intrauterine devices (IUDs)

https://libcat.nshealth.ca/en/permalink/chpams36577
Nova Scotia Health Authority. Nova Scotia Women's Choice Clinic. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
2006
Available Online
View Pamphlet
A hormonal intrauterine device (IUD) is a small device made of flexible plastic with a hormone called levonorgestrel that is placed inside the uterus by a primary health care provider (family doctor or nurse practitioner). It is used to prevent pregnancy. This pamphlet explains how a hormonal IUD works, the pros and cons of a hormonal IUD, what will happen when the IUD is inserted, movement or loss of the IUD, and IUD removal. A list of symptoms that require immediate medical attention is also …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Women's Choice Clinic
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document (8 p.) : digital, PDF file
Subjects (MeSH)
Intrauterine Devices
Contraception - methods
Subjects (LCSH)
Intrauterine contraceptives
Contraception
Abstract
A hormonal intrauterine device (IUD) is a small device made of flexible plastic with a hormone called levonorgestrel that is placed inside the uterus by a primary health care provider (family doctor or nurse practitioner). It is used to prevent pregnancy. This pamphlet explains how a hormonal IUD works, the pros and cons of a hormonal IUD, what will happen when the IUD is inserted, movement or loss of the IUD, and IUD removal. A list of symptoms that require immediate medical attention is also provided. The French version of this pamphlet 2019, "Dispositif hormonal intra-utérin (avec lévonorgestrel) (DIU)", is also available.
Responsibility
Prepared by: Nova Scotia Women's Choice Clinic
Pamphlet Number
2006
Less detail

Hormone therapy for prostate cancer

https://libcat.nshealth.ca/en/permalink/chpams37500
Nova Scotia Health Authority. GU Cancer Site Team. [Halifax, NS]: Nova Scotia Health Cancer Care Program , 2021.
Pamphlet Number
4010
Available Online
View Pamphlet
The prostate is a gland that makes seminal fluid. Prostate cancer is a disease where cancer cells start to grow in the prostate gland. These cancer cells grow into a tumor and can spread to other parts of the body such as the bones and lymph nodes. This pamphlet explains what causes prostate cancer, what hormones are, what testosterone does, how hormone therapy works for prostate cancer, how long you will be on hormone therapy, and side effects. A list of resources for further information is pr…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. GU Cancer Site Team
Place of Publication
[Halifax, NS]
Publisher
Nova Scotia Health Cancer Care Program
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.) : digital, PDF file
Subjects (MeSH)
Prostatic Neoplasms
Hormones
Subjects (LCSH)
Prostate--Cancer--Treatment
Specialty
Cancer Care
Urogenital System
Abstract
The prostate is a gland that makes seminal fluid. Prostate cancer is a disease where cancer cells start to grow in the prostate gland. These cancer cells grow into a tumor and can spread to other parts of the body such as the bones and lymph nodes. This pamphlet explains what causes prostate cancer, what hormones are, what testosterone does, how hormone therapy works for prostate cancer, how long you will be on hormone therapy, and side effects. A list of resources for further information is provided.
Responsibility
Prepared by: GU Cancer Site Team; Approved by: Nova Scotia Cancer Patient Education Committee
Pamphlet Number
4010
Less detail

Parathyroidectomy and kidney disease

https://libcat.nshealth.ca/en/permalink/chpams34702
Nova Scotia Health Authority. Nephrology/Dialysis Services. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
0739
Available Online
View Pamphlet
Parathyroidectomy is a surgery that removes your parathyroid glands. Your parathyroid glands are in your neck (usually on the back of the thyroid gland). They help to control your blood calcium and phosporous levels. Hyperparathyroidism is when one or more of the parathyroid glands makes too much parathyroid hormone in your blood. If this happens, you will need a parathyroidectomy. This pamphlet explains what a parathyroidectomy is, the possible complications with this surgery, care after surge…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nephrology/Dialysis Services
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Parathyroidectomy
Kidney Diseases
Subjects (LCSH)
Parathyroidectomy
Kidneys--Diseases
Specialty
Nephrology
Surgery
Abstract
Parathyroidectomy is a surgery that removes your parathyroid glands. Your parathyroid glands are in your neck (usually on the back of the thyroid gland). They help to control your blood calcium and phosporous levels. Hyperparathyroidism is when one or more of the parathyroid glands makes too much parathyroid hormone in your blood. If this happens, you will need a parathyroidectomy. This pamphlet explains what a parathyroidectomy is, the possible complications with this surgery, care after surgery, how to take care of your incision, blood work, medications, and symptoms that need medical attention right away. A medication chart is included.
Responsibility
Prepared by: Nephrology/Dialysis Services
Pamphlet Number
0739
Less detail

What is the Oncotype DX test?

https://libcat.nshealth.ca/en/permalink/chpams37365
Nova Scotia Health. Cancer Care Program. Halifax, NS: Nova Scotia Health Cancer Care Program , 2023.
Pamphlet Number
4047
Available Online
View Pamphlet
Oncotype DX is a test panel used to help predict whether a patient with breast cancer could benefit from chemotherapy in addition to hormone therapy. The panel tests multiple specific tumor genes and generates a score which helps predict response to chemotherapy. The genes tested are those expressed by the tumor, not genes that you inherit from your parents our pass along to your children. This pamphlet gives information to help you decide if the Oncotype Dx test is right for you.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health. Cancer Care Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Cancer Care Program
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Breast Neoplasms - diagnosis
Genes, Neoplasm
Genetic Testing
Subjects (LCSH)
Breast--Cancer--Diagnosis
Cancer genes
Human chromosome abnormalities--Diagnosis
Specialty
Cancer Care
Breast Disease
Abstract
Oncotype DX is a test panel used to help predict whether a patient with breast cancer could benefit from chemotherapy in addition to hormone therapy. The panel tests multiple specific tumor genes and generates a score which helps predict response to chemotherapy. The genes tested are those expressed by the tumor, not genes that you inherit from your parents our pass along to your children. This pamphlet gives information to help you decide if the Oncotype Dx test is right for you.
Responsibility
Prepared by: Nova Scotia Health Cancer Care Program
Pamphlet Number
4047
Less detail

8 records – page 1 of 1.